Alfred Ian Lee, MD, PhD

Assistant Professor of Medicine (Hematology); Firm Chief, Inpatient Hematology, Yale Cancer Center; Assistant Program Director, Traditional Internal Medicine Residency Program

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Internal Medicine: Hematology

Cancer Center: Hematology Program

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Internal Medicine AB of Internal Medicine (2007)

  • Hematology (Internal Medicine) AB of Internal Medicine (2013)

Clinical Trials

Conditions Study Title
Myeloid and Monocytic Leukemia A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)
Leukemia, other A Phase I, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Leukemia, other A Phase I/II Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
Myeloid and Monocytic Leukemia, Phase I A Phase I, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Acute Myeloid Leukemia and High-Risk Myelodsplastic Syndrome
Myeloid and Monocytic Leukemia, Phase I A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS
Leukemia, other A Phase III Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Leukemia, other, Phase I A Phase I Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Hodgkin's Lymphoma, Leukemia, other, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Hematopoietic, Phase I An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Myeloid and Monocytic Leukemia An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects

Edit this profile

Contact Info

Alfred Ian Lee, MD, PhD
Patient Care Location
Yale HematologySmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste North Pavilion 7

New Haven, CT 06511
View on map...
Mailing Address
333 Cedar Street
PO Box 208028

New Haven, CT 06520-8028